Abstract
The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58%, 41% and 25% of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bacus SS, Chin D, Yarden Y, Zelnick CR and Stern DF (1996) Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148: 549–558
Baulida J, Kraus MH, Alimandi M, Di Fiore PP and Carpenter G (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251–5257
Bridges AJ (1996) The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target?. Curr Med Chem 3: 167–194
Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA, Comrack CA, Dussault BJ, Woolf J, Goodearl AD and Gearing DP (1997) Characterisation of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol 17: 4007–4014
Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Ann Rev Biochem 56: 881–914
Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gasmann M and Lai C (1997) Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 387: 512–516
Chang C-P, Lazar CS, Walsh BJ, Komuro M, Collawn JF, Kuhn LA, Tainer JA, Trowbridge IS, Farguhar MG, Rosenfeld MG, Wiley HS and Gill GN (1993) Ligand-induced internalization of the epidermal growth factor receptor is mediated by multiple endocytic codes analogous to the tyrosine motif found in constitutively internalized receptors. J Biol Chem 268: 19312–19320
Chang H, Riese DJ, Gilbert W, Stern DF and McMahan UJ (1997) Ligands for the ErbB family receptors encoded by a neuregulin-like gene. Nature 387: 509–512
Earp HS, Dawson TL, Lix, and Yu H (1995) Heterodimerisation and functional interaction between EGF receptor family members: a new signalling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115–132
Elenius K, Paul S, Allison G, Sun J and Klagsbrun M (1997 a) Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16: 1268–1278
Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD and Klagsbrun M (1997 b) A novel juxtamembrane domain isoform of HER4/ErbB4. J Biol Chem 272: 26761–26768
Ellis IO, Galea M, Broughton N, Locker A, Blamey RW and Elston CW (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20: 479–489
Elston CW and Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410
Faksvag Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR (1996) Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res 56: 1184–1188
Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R and Lemke G (1995) Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378: 390–394
Gilbertson RJ, Perry RH, Kelly PJ, Pearson ADJ and Lunec J (1997) Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272–3280
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI and Griffiths K (1982) A prognostic index in primay breast cancer. Br J Cancer 45: 361–366
Higashiyama S, Horikawa M, Yamada K, Ichino N, Nakano N, Nakagawa T, Miyagawa J, Matsushita N, Nagatsu T, Taniguchi N and Ishiguro H (1997) A novel brain derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J Biochem 122: 675–680
Hollywood DP and Hurst HC (1993) A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12: 2369–2375
Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang W-J, Wood WI, Goeddel DV and Vandlen RL (1992) Identification of heregulin, a specific activator of p185erbB2. Science 256: 1205–1210
Kageyama R, Merlino T and Pastan I (1988) Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem 263: 6329–6336
Klijn JGM, Berns PMJJ, Schmitz PIM and Foekens JA (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev 13: 3–17
Komurasaki T, Toyoda H, Uchida D and Morimoto S (1997) Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 15: 2841–2848
Knowlden JM, Gee JMW, Seery LP, Farrow L, Gullick WJ, Ellis IO, Blamey RWB, Robertson JFR and Nicholson RI (1998) c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17: 1949–1957
Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ and Hurst HC (1992) Expression of the ERBB3 gene-product in breast cancer. Br J Cancer 66: 1116–1121
Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, Blamey RW and IO ELLIS (1990) Expression of epidermal growth factor receptor in breast carcinoma. Clin Pathol 43: 385–389
Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD and Sliwkowski MX (1996) Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 56: 1457–1465
Li W, Park JW, Nuijens A, Sliwkowski MX and Keller GA (1996) Heregulin is rapidly translocated to the nucleus and its transport is correlated with c- myc induction in breast cancer cells. Oncogene 12: 2473–2477
Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW and Blamey RW (1991) C-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443
Lyne JC, Melham MF, Finley GG, Wen D, Liu N, Deng DH and Salup R (1997) Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Scientific American 3: 21–30
Mason S and Gullick WJ (1995) Type 1 growth factor receptors: an overview of recent developments. The Breast 4: 11–18
Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, Robertson JFR and Ellis IO (1995) Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 27: 219–226
Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW and Elston CW (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopath 24(1): 41–47
Plowman GD, Culouscou J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG and Shoyab M (1993 a) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746–1750
Plowman GD, Green JM, Culouscou J-M, Carlton GW, Rothwell VM and Buckley S (1993 b) Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366: 473–475
Riese DJ, Bermingham Y, Van Raaij TM, Buckley S, Plowman GD and Stern DF (1996) Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogene 12: 345–353
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235: 177–182
Srinivasan R, Poulsom R, Hurst HC and Gullick WJ (1998) Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Path 185: 236–245
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW and Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489–492
Travis A, Pinder SE, Robertson JFR, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blarney RW, Elston CW and Ellis IO (1996) C-erbB3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. British Journal of Cancer 74: 229–233
Vecchi M and Carpenter G (1997) Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J Cell Biol 139: 995–1003
Vecchi M, Baulida J and Carpenter G (1996) Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J Biol Chem 271: 18989–18995
Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Janssen AM, Ben-Baruch N, Trollinger DB and Jacobsen VL (1994) Structural and functional aspects of the multiplicity of neu differentiation factors. Mol Cell Biol 14: 1909–1919
Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J and Godowski PJ (1997) Neuregulin 3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 94: 9562–9567
Zhu X, Lai C, Thomas S and Burden SJ (1995) Neuregulin receptors, erbB3 and erbB4 are localized at neuromuscular synapses. EMBO J 14: 5842–5848
Zimonjic DB, Alimandi M, Miki T, Popescu NC and Kraus MH (1995) Localization of the human HER4/erbB-4 gene to chromosome 2. Oncogene 10: 1235–1237
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kew, T., Bell, J., Pinder, S. et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer 82, 1163–1170 (2000). https://doi.org/10.1054/bjoc.1999.1057
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1057
Keywords
This article is cited by
-
ErbB4 3′-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer
Indian Journal of Clinical Biochemistry (2020)
-
The role of ADAM17 in tumorigenesis and progression of breast cancer
Tumor Biology (2016)
-
Significance of epidermal growth factor receptor expression in breast cancer
Medical Oncology (2011)
-
WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer
Oncogene (2009)
-
HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer
Journal of Mammary Gland Biology and Neoplasia (2008)